Product Code: ETC5306050 | Publication Date: Nov 2023 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 60 | No. of Figures: 30 | No. of Tables: 5 |
The pneumonia vaccine market in Canada is influenced by public health initiatives and increasing awareness of respiratory diseases. The demand for vaccines is supported by government health programs and advancements in vaccine technology.
The increasing incidence of pneumonia, particularly among the elderly and immunocompromised individuals, is driving the demand for pneumonia vaccines in Canada. Public health initiatives and vaccination programs aimed at reducing the burden of pneumococcal diseases have significantly boosted the market. The growing awareness of the importance of vaccination, along with government funding and support for immunization programs, is further contributing to market growth. Additionally, the introduction of new and improved vaccines, including combination vaccines, is enhancing the markets expansion.
The pneumonia vaccine market in Canada encounters challenges related to the high cost of vaccine development and production, as well as regulatory approval processes. Ensuring that vaccines meet efficacy and safety standards while addressing competition from other vaccine options is crucial. The market must also navigate fluctuations in healthcare funding, manage production costs, and adapt to evolving public health needs and vaccination policies.
The pneumonia vaccine market in Canada is influenced by government policies that support public health and vaccination programs. The Canadian government provides funding for research and development in pneumonia vaccines and sets regulations to ensure vaccine safety and efficacy. Policies promote the use of pneumonia vaccines to prevent respiratory infections and improve public health outcomes.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Canada Pneumonia Vaccine Market Overview |
3.1 Canada Country Macro Economic Indicators |
3.2 Canada Pneumonia Vaccine Market Revenues & Volume, 2021 & 2031F |
3.3 Canada Pneumonia Vaccine Market - Industry Life Cycle |
3.4 Canada Pneumonia Vaccine Market - Porter's Five Forces |
3.5 Canada Pneumonia Vaccine Market Revenues & Volume Share, By Vaccine Type, 2021 & 2031F |
3.6 Canada Pneumonia Vaccine Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 Canada Pneumonia Vaccine Market Revenues & Volume Share, By Sector, 2021 & 2031F |
3.8 Canada Pneumonia Vaccine Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Canada Pneumonia Vaccine Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about the importance of vaccination in preventing pneumonia |
4.2.2 Rising geriatric population in Canada leading to higher demand for pneumonia vaccines |
4.2.3 Government initiatives and programs promoting vaccination against pneumonia |
4.3 Market Restraints |
4.3.1 High cost associated with pneumonia vaccines limiting affordability for some segments of the population |
4.3.2 Limited access to healthcare services in remote regions impacting the distribution of vaccines |
5 Canada Pneumonia Vaccine Market Trends |
6 Canada Pneumonia Vaccine Market Segmentations |
6.1 Canada Pneumonia Vaccine Market, By Vaccine Type |
6.1.1 Overview and Analysis |
6.1.2 Canada Pneumonia Vaccine Market Revenues & Volume, By Pneumococcal Conjugate Vaccine, 2021-2031F |
6.1.3 Canada Pneumonia Vaccine Market Revenues & Volume, By Pneumococcal Polysaccharide Vaccine, 2021-2031F |
6.2 Canada Pneumonia Vaccine Market, By Product Type |
6.2.1 Overview and Analysis |
6.2.2 Canada Pneumonia Vaccine Market Revenues & Volume, By Prevnar 13, 2021-2031F |
6.2.3 Canada Pneumonia Vaccine Market Revenues & Volume, By Synflorix, 2021-2031F |
6.2.4 Canada Pneumonia Vaccine Market Revenues & Volume, By Pneumovax 23, 2021-2031F |
6.3 Canada Pneumonia Vaccine Market, By Sector |
6.3.1 Overview and Analysis |
6.3.2 Canada Pneumonia Vaccine Market Revenues & Volume, By Public, 2021-2031F |
6.3.3 Canada Pneumonia Vaccine Market Revenues & Volume, By Private, 2021-2031F |
6.4 Canada Pneumonia Vaccine Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Canada Pneumonia Vaccine Market Revenues & Volume, By Distribution Partner Companies, 2021-2031F |
6.4.3 Canada Pneumonia Vaccine Market Revenues & Volume, By Non-governmental Organizations (NGO), 2021-2031F |
6.4.4 Canada Pneumonia Vaccine Market Revenues & Volume, By Government Authorities, 2021-2031F |
7 Canada Pneumonia Vaccine Market Import-Export Trade Statistics |
7.1 Canada Pneumonia Vaccine Market Export to Major Countries |
7.2 Canada Pneumonia Vaccine Market Imports from Major Countries |
8 Canada Pneumonia Vaccine Market Key Performance Indicators |
8.1 Percentage increase in vaccination coverage rates among high-risk populations |
8.2 Number of pneumonia-related hospitalizations in Canada |
8.3 Rate of pneumonia cases in children under 5 years old |
9 Canada Pneumonia Vaccine Market - Opportunity Assessment |
9.1 Canada Pneumonia Vaccine Market Opportunity Assessment, By Vaccine Type, 2021 & 2031F |
9.2 Canada Pneumonia Vaccine Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.3 Canada Pneumonia Vaccine Market Opportunity Assessment, By Sector, 2021 & 2031F |
9.4 Canada Pneumonia Vaccine Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Canada Pneumonia Vaccine Market - Competitive Landscape |
10.1 Canada Pneumonia Vaccine Market Revenue Share, By Companies, 2024 |
10.2 Canada Pneumonia Vaccine Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations | 13 Disclaimer |